Implementation of a standardized, equitable multi-omic pathway to resolve undiagnosed pediatric neurogenetic disease
Short-read genome sequencing (GS) has become a powerful first-tier test for children with suspected neurogenetic disease, yet its diagnostic yield plateaus near 40%, leaving most families without an answer. The undiagnosed remainder is not one problem but a collection of mechanistically distinct lesions, including cryptic splice-altering and regulatory variants, repeat expansions, and complex structural rearrangements, frequently missed or uninterpretable on short-read GS. Layering GS with RNA sequencing (RNA-seq) and long-read sequencing (LRS) resolves many of these cases. The central challenge is no longer whether multi-omic methods add diagnostic power, but how to deliver them as a routine, standardized, and equitable clinical service rather than an ad hoc research effort. Here we describe an integrated multi-omic diagnostic pathway built across the University of Utah and Primary Children’s Hospital for a largely rural, underserved catchment area. The pathway couples uniform GS delivery (the NeoSeq, TeleGenetics, and Gene Kids programs) with AI-assisted patient identification (Mendelian Phenotype Search Engine, MPSE) and a registry of non-diagnostic genomes subjected to multi-omic reanalysis (Neo/ReSeq). We focus on the design questions that determine whether multi-omics succeeds at scale: which modality to deploy for which patient, how source-tissue selection governs RNA-seq interpretability, how to allocate finite RNA-seq and LRS capacity, and how to embed equity so its power does not accrue only to the already-advantaged. We emphasize the architecture rather than cohort results, which are reported separately, and argue that an integrated, lifelong multi-omic strategy is the realistic path to closing the diagnostic gap in pediatric neurogenetic disease.
Authors
- Pınar Bayrak‐Toydemir (ORCID: https://orcid.org/0000-0001-9381-2478)
- Rong Mao (ORCID: https://orcid.org/0000-0002-3549-4069)
- Rachel N. Palmquist
- Steven E. Boyden (ORCID: https://orcid.org/0000-0002-9334-1466)
- Brian J. Shayota (ORCID: https://orcid.org/0000-0003-4657-6454)
- Tanner Ellsworth
- Chelsea M. Solorzano
- Joselín Hernández-Ruiz (ORCID: https://orcid.org/0000-0002-0571-2563)
- Thomas J. Nicholas (ORCID: https://orcid.org/0000-0002-4198-6414)
- Joshua L. Bonkowsky (ORCID: https://orcid.org/0000-0001-8775-147X)
- Shawn G. Rynearson
- Makenna Beigh
- Carson Holt (ORCID: https://orcid.org/0000-0002-9864-0019)
- V. Taliercio
- Steven B. Bleyl
- Julie M. Porter
- John Larson
- Melanie Emmerson
- S Malone Jenkins
- Bennet Peterson
- Betsy Ostrander
- Barry Moore
- Mark Yandell
- Evy Clark
- Martin Tristani-Firouzi
- Hannah Happ
- Marco Marchetti
Institutions
- Intermountain Healthcare (US)
- Primary Children's Hospital (US)
- University of Utah (US)
- ARUP Laboratories (United States) (US)
- ARUP Laboratories (United States) (US)
Publication Details
- Journal
- Frontiers in Genetics
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fgene.2026.1955129
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- R. Harold Burton Foundation
- Warren Alpert Foundation
- Ben B. and Iris M. Margolis Foundation
- University of Utah
- ARUP Laboratories
- National Institute for Health and Care Research
- National Institutes of Health